Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Summary

This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of KL001 injection solution in hemophilia B subjects with ≤2 IU/dl residual FIX levels.

Timeline

Start

2023-11-20

Primary completion

2024-06-30

Completion

2025-07-10

Drugs

Indications